Singapore, November 29, 2021 – In response to the new variant strain Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on November 29th, 2021.
According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay is capable of detecting the new variant strain correctly.
As the analysis result was based on limited sequence data currently published, we will continue to monitor and collect the sequence data to verify the impact of this new emerging variant on assay performance.
Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly.
Another four Variants of Concern (VOC):
． Alpha variant: known as B.1.1.7 or UK variant
． Beta variant: known as B.1.351 or South Africa variant
． Gamma variant: known as P.1 or Brazil variant
． Delta variant: known as B.1.617.2 or Indian variant
Two Variants of Interest (VOI):
． Lambda variant: known as C.37 or Peru variant
． Mu variant: known as B.1.621 or Colombia variant
The other six variants:
． Eta variant: known as B.1.525
． Iota variant: known as B.1.526
． Kappa variant: known as B.1.617.1 or Indian variant
． Zeta variant: known as P.2 or Brazil variant
． Epsilon variant: known as B.1.427/B.1.429 or United States variant
． Indian variant: known as B.1.617.3
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.